Lacutamab in patients (pts) with advanced mycosis fungoides (MF) according to KIR3DL2 expression: early results from the TELLOMAK phase 2 trial Bagot, M., Kim, Y., Zinzani, P., Dalle, S., Beylot-Barry, M., Ortiz-Romero, P. L., Cambalia, A., Dereure, O., Mortier, L., Jacobsen, E., Battistella, M., Gru, A., Moins-Teisserenc, H., Paiva, C., Boyer-Chammard, A., Rotolo, F., Azim, H. A., Porcu, P. ELSEVIER SCI LTD. 2021: S20-S21

View details for Web of Science ID 000719152800039